Table 3.

Results from the multivariate regression models (before adjustment for multiple testing via gatekeeping procedure) using multiple imputation of missing values and double-robust adjustment for EFS and OS in the full analysis set

EFSOS
VariableHR95% CIPVariableHR95% CIP
Entire cohort (N = 855) 
 AMLSG 16-10 0.55 0.47-0.65 <.001 AMLSG 16-10 0.56 0.47-0.68 <.001 
 Age (10-y increase) 1.17 1.09-1.25 <.001 Age, y 1.33 1.23-1.44 <.001 
 Female 0.91 0.78-1.07 .255 Female 0.90 0.75-1.07 .241 
 NPM1-mutated 0.48 0.41-0.57 <.001 NPM1-mutated 0.76 0.63-0.91 .002 
 WBC (log10) 1.21 1.05-1.40 .011 WBC (log10) 1.23 1.04-1.44 .015 
 BM blasts 0.94 0.62-1.44 .788 BM blasts 1.16 0.73-1.87 .528 
 FLT3-ITDhigh 1.21 1.00-1.48 .052 FLT3-ITDhigh 1.20 0.98-1.47 .082 
Younger patients (18-60 y) (n = 664) 
 AMLSG 16-10 0.59 0.49-0.71 <.001 AMLSG 16-10 0.59 0.47-0.73 <.001 
 Age (10-y increase) 1.16 1.06-1.27 <.001 Age, y 1.30 1.17-1.45 <.001 
 Female 0.97 0.80-1.16 .709 Female 0.99 0.80-1,22 .893 
 NPM1-mutated 0.47 0.39-0.56 <.001 NPM1-mutated 0.76 0.61-0.94 .010 
 WBC (log10) 1.24 1.04-1.47 .014 WBC (log10) 1.23 1.01-1.49 .037 
 BM blasts 0.99 0.62-1.60 .978 BM blasts 1.41 0.81-2.45 .219 
 FLT3-ITDhigh 1.15 0.93-1.42 .194 FLT3-ITDhigh 1.14 0.90-1.45 .284 
Older patients (61-70 y) (n = 191) 
 AMLSG 16-10 0.41 0.29-0.59 <.001 AMLSG 16-10 0.47 0.33-0.67 <.001 
 Age (10-y increase) 1.36 0.75-2.47 .301 Age, y 1.27 0.67-2.40 .456 
 Female 0.74 0.53-1.04 .082 Female 0.70 0.49-0.99 .042 
 NPM1-mutated 0.53 0.38-0.74 <.001 NPM1-mutated 0.75 0.53-1.08 .118 
 WBC (log10) 1.09 0.82-1.44 .550 WBC (log10) 1.15 0.84-1.56 .378 
 BM blasts 0.65 0.27-1.56 .329 BM blasts 0.57 0.22-1.47 .245 
 FLT3-ITDhigh 1.48 0.96-2.29 .078 FLT3-ITDhigh 1.44 0.92-2.27 .111 
EFSOS
VariableHR95% CIPVariableHR95% CIP
Entire cohort (N = 855) 
 AMLSG 16-10 0.55 0.47-0.65 <.001 AMLSG 16-10 0.56 0.47-0.68 <.001 
 Age (10-y increase) 1.17 1.09-1.25 <.001 Age, y 1.33 1.23-1.44 <.001 
 Female 0.91 0.78-1.07 .255 Female 0.90 0.75-1.07 .241 
 NPM1-mutated 0.48 0.41-0.57 <.001 NPM1-mutated 0.76 0.63-0.91 .002 
 WBC (log10) 1.21 1.05-1.40 .011 WBC (log10) 1.23 1.04-1.44 .015 
 BM blasts 0.94 0.62-1.44 .788 BM blasts 1.16 0.73-1.87 .528 
 FLT3-ITDhigh 1.21 1.00-1.48 .052 FLT3-ITDhigh 1.20 0.98-1.47 .082 
Younger patients (18-60 y) (n = 664) 
 AMLSG 16-10 0.59 0.49-0.71 <.001 AMLSG 16-10 0.59 0.47-0.73 <.001 
 Age (10-y increase) 1.16 1.06-1.27 <.001 Age, y 1.30 1.17-1.45 <.001 
 Female 0.97 0.80-1.16 .709 Female 0.99 0.80-1,22 .893 
 NPM1-mutated 0.47 0.39-0.56 <.001 NPM1-mutated 0.76 0.61-0.94 .010 
 WBC (log10) 1.24 1.04-1.47 .014 WBC (log10) 1.23 1.01-1.49 .037 
 BM blasts 0.99 0.62-1.60 .978 BM blasts 1.41 0.81-2.45 .219 
 FLT3-ITDhigh 1.15 0.93-1.42 .194 FLT3-ITDhigh 1.14 0.90-1.45 .284 
Older patients (61-70 y) (n = 191) 
 AMLSG 16-10 0.41 0.29-0.59 <.001 AMLSG 16-10 0.47 0.33-0.67 <.001 
 Age (10-y increase) 1.36 0.75-2.47 .301 Age, y 1.27 0.67-2.40 .456 
 Female 0.74 0.53-1.04 .082 Female 0.70 0.49-0.99 .042 
 NPM1-mutated 0.53 0.38-0.74 <.001 NPM1-mutated 0.75 0.53-1.08 .118 
 WBC (log10) 1.09 0.82-1.44 .550 WBC (log10) 1.15 0.84-1.56 .378 
 BM blasts 0.65 0.27-1.56 .329 BM blasts 0.57 0.22-1.47 .245 
 FLT3-ITDhigh 1.48 0.96-2.29 .078 FLT3-ITDhigh 1.44 0.92-2.27 .111 

BM, bone marrow.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal